The pharmaceutical industry is undergoing a transformative shift driven by artificial intelligence (AI), which is revolutionizing drug discovery, clinical trials, and manufacturing processes. This chapter explores the future trends and innovations in AI-driven drug development, focusing on the integration of AI with robotics and automation, the role of AI in decentralized clinical trials, and the disruptive potential of quantum computing and next-generation AI models. ​ Key advancements include AI-powered automation in the design, make, test, and analyze (DMTA) cycle, predictive analytics in manufacturing and supply chains, and the use of digital twins in clinical trials. Quantum computing offers unprecedented precision in molecular simulations, while next-generation AI models, such as foundation and generative models, enable the creation of novel molecular structures. The chapter also addresses the challenges of adopting these technologies, including data quality, regulatory hurdles, and ethical considerations. A strategic roadmap emphasizes the importance of ethical frameworks, collaborative ecosystems, and equitable access to ensure AI benefits all communities. ​ Together, these innovations promise to accelerate timelines, reduce costs, and enhance the quality of drug development, paving the way for safer, more effective therapies. ​.